Handelsbanken Fonder AB Buys 300 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Handelsbanken Fonder AB increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 0.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,200 shares of the medical research company’s stock after acquiring an additional 300 shares during the period. Handelsbanken Fonder AB’s holdings in Exact Sciences were worth $2,530,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXAS. Artisan Partners Limited Partnership raised its stake in Exact Sciences by 11.8% in the third quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock valued at $270,254,000 after buying an additional 418,770 shares during the period. Qube Research & Technologies Ltd raised its stake in Exact Sciences by 328.3% in the third quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company’s stock valued at $36,852,000 after buying an additional 414,059 shares during the period. Victory Capital Management Inc. raised its stake in Exact Sciences by 230.8% in the third quarter. Victory Capital Management Inc. now owns 510,388 shares of the medical research company’s stock valued at $34,819,000 after buying an additional 356,084 shares during the period. Jennison Associates LLC raised its stake in Exact Sciences by 55.5% in the third quarter. Jennison Associates LLC now owns 701,682 shares of the medical research company’s stock valued at $47,869,000 after buying an additional 250,501 shares during the period. Finally, Armistice Capital LLC raised its stake in Exact Sciences by 50.7% in the third quarter. Armistice Capital LLC now owns 711,520 shares of the medical research company’s stock valued at $48,540,000 after buying an additional 239,520 shares during the period. Institutional investors own 88.82% of the company’s stock.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,341.38. Following the sale, the insider now owns 7,488 shares of the company’s stock, valued at approximately $459,987.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,341.38. Following the sale, the insider now owns 7,488 shares of the company’s stock, valued at approximately $459,987.84. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin T. Conroy sold 14,791 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $908,611.13. Following the completion of the sale, the chief executive officer now directly owns 1,224,357 shares in the company, valued at approximately $75,212,250.51. The disclosure for this sale can be found here. In the last quarter, insiders have sold 69,113 shares of company stock valued at $4,165,273. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on EXAS. William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Citigroup reaffirmed a “buy” rating and issued a $100.00 target price on shares of Exact Sciences in a research report on Wednesday, April 3rd. TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 target price on the stock in a research report on Tuesday, January 2nd. Finally, Canaccord Genuity Group decreased their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $97.44.

Exact Sciences Trading Up 0.1 %

Shares of NASDAQ:EXAS opened at $58.85 on Friday. The company has a market capitalization of $10.68 billion, a P/E ratio of -51.62 and a beta of 1.25. Exact Sciences Co. has a 1 year low of $56.05 and a 1 year high of $100.77. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The business’s 50 day simple moving average is $63.44 and its 200 day simple moving average is $64.95.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.72) EPS. On average, research analysts anticipate that Exact Sciences Co. will post -0.86 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.